TABLE OF CONTENTS
Chapter 1: Executive Summary
- Technology Background
- The Industry Environment
- Technologies
- Products and Applications
- Market Dynamics
- Future Trends
- References
Chapter 2: Introduction
- Post-Genomic Biomarkers: From Discovery to Implementation
- Nature of This Report
Chapter 3: Technology Background
Chapter 4: The Industry Environment
Chapter 5: Technologies
- Pre-genomic Methods for Biomarker Discovery and Detection
- Post-genomic Methods for Biomarker Discovery and Detection
- Transcriptomics
- Positional DNA Microarrays
- Encoded Bead Arrays
- Proteomics
- Metabolomics
- Imaging
- PET and SPECT Imaging
- Magnetic Resonance Imaging.
- Computed Tomography Imaging
- Optical Imaging
- References
Chapter 6: Products and Applications
- Biomarkers in Drug Discovery and Development
- Examples of Biomarker Development
- Biomarkers in Drug Discovery
- Biomarkers in Lead Optimization and Preclinical Development
- Biomarkers in Clinical Development.
- Regulatory Perspectives on Pharmaceutical Biomarkers
- Biomarkers in Diagnostics
- Historical Aspects of Diagnostic Biomarkers
- Biomarkers in Cancer Diagnostics
- Commercial Cancer Diagnosis Activity
- Diagnostic Biomarkers for Other Diseases
- General Biomarker Products and Services
- Transcriptomics
- Proteomics
- Metabolomics
- Imaging Biomarkers
- Commercial Imaging Biomarker Offerings
- References
Chapter 7: Market Dynamics
- Conclusions from the Survey
Chapter 8: Company Profiles
- Aclara Biosciences
- Applied Biosystems
- Beyond Genomics
- BioVision AG
- Bruker Daltonics, Inc
- Caprion Pharmaceuticals, Inc
- Ciphergen Biosystems
- Compugen Ltd
- Correlogic Systems, Inc
- CTI Molecular Imaging, Inc
- Epigenomics AG
- GE Healthcare
- Health Discovery Corporation
- IBEX Technologies Inc
- Icoria, Inc. (Previously Paradigm Genetics)
- Metabolon, Inc.
- Power 3 Medical Products, Inc
- Predictive Diagnostics, Inc
- Predicant Biosciences
- Proteome Sciences plc
- SurroMed, Inc
- Synarc, Inc
- TheRyte, Ltd
- VirtualScopics LLC
Chapter 9: Future Trends
Chapter 10: Interviews With Industry Experts
- Brian Edmonds, Ph.D., Manager, New Technologies, Eli Lilly
- Donald A. Berry, Ph.D., Professor of Biostatistics, Chairman Department of Biostatistics and Applied Mathematics, Chief Section of Biostatistics,
- Frank T. McGraw Memorial Chair for Cancer Research U Texas M.D. Anderson Cancer Center
- Deborah Neff, President & CEO, Predicant Biosciences.
- Peter Steiger, Ph.D., President and CEO, Synarc, Inc.
- Michael Spain, M.D., Chief Medical Officer, Rules Based Medicine.
- John Ryals, Ph.D., President and Chief Executive Officer, Metabolon
- Homer Pien, Ph.D., Managing Director, MGH-HST Center for Biomarkers in Imaging
- Mark Flocco, Business Development Manager for Clinical Proteomics, Bruker Daltonics
TABLE OF EXHIBITS
- Exhibit 3.1 Examples of Surrogate Endpoints for Drug Development
- Exhibit 3.2 The Pfizer Biomarker Classification Scheme
- Exhibit 5.1 The Affymetrix Microarray Assay Process
- Exhibit 5.2 The Affymetrix Photolithographic Array Production Process
- Exhibit 5.3 The Aclara eTag® Technology
- Exhibit 5.4 High Throughput Genomics Multiplexed Gene Expression Detection Technology
- Exhibit 5.5 Ciphergen ProteinChip® Technology
- Exhibit 5.6 Ciphergen Biomarker Discovery Technology
- Exhibit 5.7 A 2D Gel Illustrating a Typical Protein Electrophorogram
- Exhibit 6.1 Beyond Genomics Generic Correlation Diagram
- Exhibit 6.2 Cancer Diagnostic Biomarker Commercialization
- Exhibit 6.3 Selected Transcriptomic Commercial Biomarker Offerings
- Exhibit 6.4 Selected Proteomic Commercial Biomarker Offerings
- Exhibit 6.5 Selected Metabolomic Commercial Biomarker Offerings
- Exhibit 6.6 Selected Systems Biology Commercial Biomarker Offerings
- Exhibit 6.7 Selected Commercial Offerings in the Imaging Biomarker Field
- Exhibit 7.1 Business Models of Biomarker-Related Companies
- Exhibit 7.2 Business Models of Biomarker Companies by Category
- Exhibit 7.3 Selected Recent Biomarker-related Deal Activity
- Exhibit 7.4 Potential Impact of Biomarkers on Pharmaceutical R&D Costs
- Exhibit 7.5 Results from a Survey of Scientists Engaged in Biomarker Work
|
Related Report
|
View Cart
